Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes

Observational Study Investigating the Efficacy of Switching From Metformin Monotherapy to a Dual Therapy of Metformin and Repaglinide on Glycaemic Control in Type 2 Diabetes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00709917

Acronym

REPAMET

Enrollment

2171

Registered

2008-07-03

Start date

2007-03-31

Completion date

2008-01-31

Last updated

2016-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This study is conducted in Europe. The aim of this observational study is to investigate the switch from metformin alone to metformin combined with repaglinide in type 2 diabetic patients not achieving adequate glycaemic control on maximal dose of metformin given alone and to analyse different epidemiological parameters.

Interventions

DRUGrepaglinide

Start dose and freqency to be prescribed by the physician at his discretion following clinical practice

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Type 2 diabetic patients with inadequate glycaemic control when received metformin alone on maximal dose * Signed informed consent * Treatment in accordance with the summary of product characterisation

Exclusion criteria

* Any contraindication to metformin or repaglinide

Design outcomes

Primary

Measure	Time frame
Safety (number of hypoglycaemic incidents)	After 10-20 weeks
HbA1C	After 10-20 weeks

Secondary

Measure	Time frame
safety	After 10-20 weeks
posology	After 10-20 weeks
lifestyle	After 10-20 weeks
FBG	After 10-20 weeks

Countries

Belgium, Luxembourg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026